Skip to search boxSkip to navigationSkip to main content

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations

  • Tai Sung Lee(corresponding author)
    ,
  • Steven J. Potts
    ,
  • Hagop Kantarjian
    ,
  • ,
  • Francis Giles
    ,
  • Maher Albitar
*Corresponding author for this work
  • University of Minnesota Twin Cities
    ,
  • Aperio Technologies
    ,
  • University of Texas MD Anderson Cancer Center
    ,
  • University of Texas Health Science Center at San Antonio
    ,
  • Quest Diagnostics Incorporated
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

BACKGROUND. Computational simulations have become powerful tools for understanding detailed interactions in biologic systems. To the authors' knowledge to date, the mechanism of imatinib resistance in BCR-ABL has not been clarified at the atomic level, and computational studies are required. METHODS. Molecular dynamics (MD) simulations on the complex of imatinib with the wild-type, T315I mutant, and 10 other P-loop mutants of the tyrosine kinase BCR-ABL were performed to study the mechanism of imatinib resistance. RESULTS. Simulations suggested that imatinib resistance of T315I results mainly comes from the breakdown of interactions between imatinib and both E286 and M290, contradictory to what was believed previously, in that the missing hydrogen bonding is the main contribution. The current results also demonstrated that the unfavorable electrostatic interaction between P-loop and imatinib is the main reason for resistance for the P-loop mutations. Furthermore, in Y253H, protonation of the histidine at the ε position, is essential for rendering this mutation resistant to imatinib. CONCLUSIONS. The current results indicated that large-scale simulations may offer insight and information that other simple modeling methods cannot provide regarding the problem of BCR-ABL imatinib resistance, especially in the case of conformational changes because of remote mutations. Imatinib resistance mechanisms that were not anticipated previously were revealed by analyzing the interactions between imatinib and individual residues based on simulation results. This results demonstrated that MD is a powerful way to verify and predict the clinical response or resistance to imatinib and to other potential drugs.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1744-1753 (10 pages)

Journal (Volume, Issue Number)

Cancer (Volume 112, Issue 8)

Publication milestones

  • Published - 04/15/2008

Publication status

Published - 04/15/2008

ISSN

0008-543X

Publication IDs

  • Scopus: 42149097162
  • PubMed: 18338744
  • ORCID: /0000-0002-8636-1071/work/68810933

Publication metrics

Metrics

SciVal
FWCI
1.43
SciVal
Author count
6
SciVal
citations
44
SciVal
Paper percentile
87
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
50
Captures
37

Funding Details

FunderFunding number
NCI
P30CA016672